cystamine has been researched along with Parkinson Disease in 2 studies
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neurodegenerative disorders are a subset of disabling pathologies characterized, in part, by a progressive and specific loss of certain brain cell populations." | 6.47 | Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases. ( Cicchetti, F; Gibrat, C, 2011) |
| "Neurodegenerative disorders are a subset of disabling pathologies characterized, in part, by a progressive and specific loss of certain brain cell populations." | 2.47 | Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases. ( Cicchetti, F; Gibrat, C, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gibrat, C | 1 |
| Cicchetti, F | 1 |
| Stack, EC | 1 |
| Ferro, JL | 1 |
| Kim, J | 1 |
| Del Signore, SJ | 1 |
| Goodrich, S | 1 |
| Matson, S | 1 |
| Hunt, BB | 1 |
| Cormier, K | 1 |
| Smith, K | 1 |
| Matson, WR | 1 |
| Ryu, H | 1 |
| Ferrante, RJ | 1 |
1 review available for cystamine and Parkinson Disease
| Article | Year |
|---|---|
Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases.
Topics: Animals; Cystamine; Cysteamine; Disease Models, Animal; Enzyme Inhibitors; Humans; Huntington Diseas | 2011 |
1 other study available for cystamine and Parkinson Disease
| Article | Year |
|---|---|
Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cystamine; Disease Models, Animal; Dru | 2008 |